Skip to content
Abierto
Menu

Award notice

human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags)

HT9425-25-D-0009

Defense Health Agency (Dha), Army Med Res Acq Activity. Research and Development in Biotechnology (except Nanobiotechnology).

View on SAM.govMarkdown

Awarded

Mapp Biopharmaceutical, Inc.

$2,000,000.00 on the award notice, May 29, 2025, contract HT9425-25-D-0009

Description

As published on SAM.gov.

Mapp Biopharmaceutical, Inc. received a Firm Fix Price Sole Source IDIQ award for the delivery of human-derived monoclonal antibodies (mAbs) and viral recombinant antigens (Ags) in support of the United States Army Medical Research Institute of Infectious Diseases (USAMRIID).

The contract, on USAspending

Federal procurement data the awarding office reported to FPDS, matched to this solicitation by its number.

Recipient
Mapp Biopharmaceutical, Inc.
UEI
M9V9QTHR1H28
CAGE
417U0
Vendor location
San Diego, CA
Contract
HT942525D0009
Obligated
$0.00, potential $2,000,000
Actions
3 between May 29, 2025 and January 13, 2026
Competition
Not Competed Under SAP, 1 offer received
Set-aside reported
No Set Aside Used.
Described as
Material Requirement for the Delivery of Antibody and Antigen Supply.
Match
award number HT942525D0009 equals the contract number; same awarding office HT9425 (high confidence)
Record
USAspending award page

Publications

Every notice SAM.gov issued under this solicitation number, oldest first. Each is a separate record on SAM.

  1. June 4, 2025

    Award notice

    Awarded to MAPP BIOPHARMACEUTICAL, Inc. San Diego for $2,000,000. SAM.gov, notice 65fa04b4fd6c44ce8952efe1b08186b0

Points of contact

Also open from this buyer